Plasma levels of Complement components C5 and C9 are associated with thrombin generation.

Complement C5 Complement C9 Proteomics Thrombin Venous Thromboembolism

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
03 Jun 2024
Historique:
received: 11 09 2023
revised: 30 03 2024
accepted: 24 04 2024
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

The thrombin generation assay (TGA) evaluates the potential of plasma to generate thrombin over time, providing a global picture of an individual's hemostatic balance. This study aimed to identify novel biological determinants of thrombin generation using a multi-omics approach. Associations between TGA parameters and plasma levels of 377 antibodies targeting 236 candidate proteins for cardiovascular risk were tested using multiple linear regression analysis in 770 individuals with venous thrombosis from the MARTHA study. Proteins associated with at least three TGA parameters were selected for validation in an independent population of 536 healthy individuals (EFS-AM). Proteins with strongest associations in both groups underwent additional genetic analyses and in vitro experiments. Eighteen proteins were associated (p<1.33x10-4) with at least three TGA parameters in MARTHA, among which 13 demonstrated a similar pattern of associations in EFS-AM. Complement proteins C5 and C9 had the strongest associations in both groups. Ex vivo supplementation of platelet-poor plasma with purified C9 protein had a significant dose-dependent effect on TGA parameters. No effect was observed with purified C5. Several single nucleotide polymorphisms associated with C5 and C9 plasma levels were identified, with the strongest association for the C5 missense variant rs17611, which was associated with a decrease in C5 levels, ETP and Peak in MARTHA. No association of this variant with TGA parameters was observed in EFS-AM. This study identified complement proteins C5 and C9 as potential determinants of thrombin generation. Further studies are warranted to establish causality and elucidate the underlying mechanisms.

Sections du résumé

BACKGROUND BACKGROUND
The thrombin generation assay (TGA) evaluates the potential of plasma to generate thrombin over time, providing a global picture of an individual's hemostatic balance.
OBJECTIVES OBJECTIVE
This study aimed to identify novel biological determinants of thrombin generation using a multi-omics approach.
METHODS METHODS
Associations between TGA parameters and plasma levels of 377 antibodies targeting 236 candidate proteins for cardiovascular risk were tested using multiple linear regression analysis in 770 individuals with venous thrombosis from the MARTHA study. Proteins associated with at least three TGA parameters were selected for validation in an independent population of 536 healthy individuals (EFS-AM). Proteins with strongest associations in both groups underwent additional genetic analyses and in vitro experiments.
RESULTS RESULTS
Eighteen proteins were associated (p<1.33x10-4) with at least three TGA parameters in MARTHA, among which 13 demonstrated a similar pattern of associations in EFS-AM. Complement proteins C5 and C9 had the strongest associations in both groups. Ex vivo supplementation of platelet-poor plasma with purified C9 protein had a significant dose-dependent effect on TGA parameters. No effect was observed with purified C5. Several single nucleotide polymorphisms associated with C5 and C9 plasma levels were identified, with the strongest association for the C5 missense variant rs17611, which was associated with a decrease in C5 levels, ETP and Peak in MARTHA. No association of this variant with TGA parameters was observed in EFS-AM.
CONCLUSIONS CONCLUSIONS
This study identified complement proteins C5 and C9 as potential determinants of thrombin generation. Further studies are warranted to establish causality and elucidate the underlying mechanisms.

Identifiants

pubmed: 38838952
pii: S1538-7836(24)00312-X
doi: 10.1016/j.jtha.2024.04.026
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Rocio Vacik Diaz (RV)

C2VN, Aix-Marseille University, INSERM, INRAE, Marseille, France; Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Gaëlle Munsch (G)

INSERM UMR_S 1219, Bordeaux Population Health Center, University of Bordeaux, Bordeaux, France.

Maria Jesus Iglesias (MJ)

Science for Life Laboratory, KTH-Royal Institute of Technology, SE-171 21 Stockholm, Sweden.

Alejandro Pallares Robles (AP)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Manal Ibrahim-Kosta (M)

C2VN, Aix-Marseille University, INSERM, INRAE, Marseille, France; Department of Hematology, CHU Timone, Marseille, France.

Jamie Nourse (J)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Essak Khan (E)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Elisabetta Castoldi (E)

Department of Biochemistry, CARIM, Maastricht University, Maastricht, the Netherlands.

Noémie Saut (N)

Department of Hematology, CHU Timone, Marseille, France.

Anne Boland (A)

Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057 Evry, France.

Marine Germain (M)

INSERM UMR_S 1219, Bordeaux Population Health Center, University of Bordeaux, Bordeaux, France.

Jean-François Deleuze (JF)

Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057 Evry, France.

Jacob Odeberg (J)

Science for Life Laboratory, KTH-Royal Institute of Technology, SE-171 21 Stockholm, Sweden.

Pierre-Emmanuel Morange (PE)

C2VN, Aix-Marseille University, INSERM, INRAE, Marseille, France; Department of Hematology, CHU Timone, Marseille, France.

Sven Danckwardt (S)

Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

David-Alexandre Tregouët (DA)

INSERM UMR_S 1219, Bordeaux Population Health Center, University of Bordeaux, Bordeaux, France.

Louisa Goumidi (L)

C2VN, Aix-Marseille University, INSERM, INRAE, Marseille, France.

Classifications MeSH